Anti-tumor and anti-inflammatory related nanoantibodies and their preparation methods and applications

By preparing the nanobody VHH02-8D specifically targeting the MMP9 catalytic domain, the problem of low selectivity of antitumor and anti-inflammatory nanobodies in the prior art has been solved, achieving effective treatment of breast cancer, colon cancer and colitis, reducing side effects and improving treatment efficacy.

CN117986368BActive Publication Date: 2024-11-29SHENZHEN UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311360682.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-18
Publication Date
2024-11-29
Estimated Expiration
2043-10-18

AI Technical Summary

Technical Problem

The lack of nanobodies in current technologies that can effectively fight both tumors and inflammation results in low selectivity and severe side effects for MMP9 inhibitors, preventing their widespread clinical application.

Method used

A nanobody VHH02-8D specifically targeting the MMP9 catalytic domain was developed. Through immunization of alpacas, PCR amplification, phage library screening and purification, a nanobody capable of efficiently inhibiting MMP9 protease activity was prepared for the preparation of anti-tumor and anti-inflammatory drugs.

Benefits of technology

The nanobody VHH02-8D can significantly inhibit the metastasis and development of breast cancer and colon cancer, and alleviate the inflammatory response of colitis. It has broad application prospects, reduces side effects, and improves the specificity and efficacy of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117986368B_ABST
    Figure CN117986368B_ABST
Patent Text Reader

Abstract

The present application relates to the field of biological science and technology, and in particular to a nano-antibody related to anti-tumor and anti-inflammatory, and its preparation method and application. A nano-antibody related to anti-tumor and anti-inflammatory is provided, the nano-antibody includes the nano-antibody VHH02-8D, wherein the amino acid sequence of the nano-antibody VHH02-8D is as shown in Seq.ID NO.1; the nano-antibody VHH02-8D can specifically bind to the tumor and inflammation-related protein MMP9, can effectively inhibit the activity of MMP9 protease, can be used as an MMP9 inhibitor, and the provided nano-antibody VHH02-8D has a good therapeutic effect in mouse breast cancer, colon cancer and inflammatory bowel disease models, and can also inhibit the activity of MMP9 enzyme to alleviate the inflammatory response of colitis, and can be used to prepare anti-tumor and anti-inflammatory related drugs, with a wide range of applications.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of biological science and technology, and in particular relates to an anti-tumor and anti-inflammatory related nano-antibody and its preparation method and application. Background Art

[0002] Matrix metalloproteinases can promote tumor metastasis and invasion by degrading extracellular matrix and play an important role in the destruction of intestinal epithelial cell barriers. Therefore, matrix metalloproteinases have always been the main target for anti-tumor and inhibition of intestinal inflammatory diseases. Matrix metalloproteinase 9 (MMP9) is an important member of the matrix metalloproteinase family. It has been shown to be highly expressed in breast cancer, colon cancer and intestinal inflammation. In addition, studies have shown that it plays a key role in tissue damage in angiogenesis, tumor metastasis and invasion, and intestinal inflammation. Therefore, blocking MMP9 provides a new strategy for tumor and inflammatory diseases.

[0003] However, most MMP9 inhibitors are small molecule broad-spectrum inhibitors, which eventually stopped clinical research due to serious side effects caused by low selectivity. In addition, although MMP9 monoclonal antibodies make up for some functional defects of small molecule inhibitors, they also failed in clinical trials because they are difficult to enter the enzyme active center of the MMP9 groove structure. Although most MMP9 inhibitors have stopped clinical trials in the treatment of cancer and inflammatory bowel disease, due to the important role they play in them, there is an urgent need for MMP9 inhibitors with higher selectivity and the ability to act on the catalytic domain.

[0004] First, nanobodies have the advantages of small molecular weight, high affinity, strong specificity and low immunogenicity, making it easy to penetrate tissue barriers, target lesions and bind to enzyme active sites, greatly reducing side effects; secondly, due to its relatively simple structure, it is easy to transform and modify, and can be coupled with small molecules or protein drugs to more effectively kill tumors or treat related diseases; and it also has good stability and can be highly expressed in prokaryotic or eukaryotic systems, so that it can reduce costs during transportation and production, making it more conducive to application. As anti-tumor and anti-inflammatory drugs, nanobodies are expected to improve the specificity and efficacy of treatment while reducing side effects, providing patients with more effective and safer treatment options. Therefore, it is urgent to provide an anti-tumor and anti-inflammatory related nanoantibody for the preparation of broad-spectrum anti-tumor and anti-inflammatory drugs for application. Summary of the invention

[0005] The purpose of the present application is to provide an anti-tumor and anti-inflammatory related nano-antibody and its preparation method and application, aiming to solve the problem in the prior art of lacking a nano-antibody with a broad spectrum that can simultaneously fight tumors and inflammation.

[0006] In order to achieve the above application purpose, the technical solution adopted in this application is as follows:

[0007] In a first aspect, the present application provides an anti-tumor and anti-inflammatory related nanoantibody, wherein the nanoantibody includes the nanoantibody VHH02-8D, wherein the amino acid sequence of the nanoantibody VHH02-8D is shown in Seq.ID NO.1.

[0008] In some embodiments, the nanobody comprises four framework regions FR1, FR2, FR3, FR4 and three complementary determining regions CDR1, CDR2, and CDR3; wherein, in the nanobody VHH02-8D, the amino acid sequence of FR1 is shown in SEQ ID NO.2, the amino acid sequence of FR2 is shown in SEQ ID NO.3, the amino acid sequence of FR3 is shown in SEQ ID NO.4, the amino acid sequence of FR4 is shown in SEQ ID NO.5, the amino acid sequence of CDR1 is shown in SEQ ID NO.6, the amino acid sequence of CDR2 is shown in SEQ ID NO.7, and the amino acid sequence of CDR3 is shown in SEQ ID NO.8.

[0009] In some embodiments, the base sequence of Nanobody VHH02-8D is as shown in Seq.ID NO.9.

[0010] In a second aspect, the present application provides a method for preparing anti-tumor and anti-inflammatory related nanobodies, comprising the following steps:

[0011] Providing anti-tumor and anti-inflammatory related target protein antigens for alpaca immunization, collecting alpaca blood and extracting cDNA, and using cDNA as a template for PCR amplification to obtain the target DNA fragment;

[0012] Connect the target DNA fragment to the vector for transformation to obtain the target DNA-vector library;

[0013] The target DNA-vector library is amplified to obtain a phage library, which is then enriched and screened, and monoclonal antibodies are expressed and purified to obtain nano-antibody sequences related to anti-tumor and anti-inflammatory effects.

[0014] In some embodiments, the anti-tumor and anti-inflammatory related target protein antigen is the MMP9 catalytic domain.

[0015] In some embodiments, the vector cell is selected from the phagemid pComb3X.

[0016] In some embodiments, in the enrichment screening step, 2 to 3 rounds of enrichment screening are performed.

[0017] In a third aspect, the present application provides the use of anti-tumor and anti-inflammatory related nano-antibodies in the preparation of drugs related to the prevention and treatment of tumors or inflammation.

[0018] In a fourth aspect, the present application provides the use of anti-tumor and anti-inflammation related nano-antibodies in the preparation of detection reagents or detection kits for detecting tumors or inflammation.

[0019] In a fifth aspect, the present application provides a drug for treating tumors or inflammation, the drug comprising anti-tumor and anti-inflammatory related nano-antibodies; wherein the tumor comprises a breast tumor or a colon tumor, and the inflammation comprises enteritis.

[0020] The first aspect of the present application provides an anti-tumor and anti-inflammatory related nanoantibody, the nanoantibody includes the nanoantibody VHH02-8D, wherein the amino acid sequence of the nanoantibody VHH02-8D is as shown in Seq.ID NO.1; the nanoantibody VHH02-8D can specifically bind to the tumor and inflammation related protein MMP9, can effectively inhibit the activity of MMP9 protease, and can serve as an MMP9 inhibitor, and the provided nanoantibody VHH02-8D has a good therapeutic effect in mouse breast cancer, colon cancer and inflammatory bowel disease models, can significantly inhibit the metastasis of breast cancer, and the development of breast cancer and colon cancer, and can also effectively alleviate the inflammatory response of colitis by inhibiting the activity of MMP9 enzyme, and can be used to prepare anti-tumor and anti-inflammatory related drugs, with a wide range of applications.

[0021] The second aspect of the present application provides a method for preparing anti-tumor and anti-inflammatory related nano-antibodies. The preparation method uses anti-tumor and anti-inflammatory related target protein antigens to immunize alpacas to obtain an immune library, and obtains specific nano-antibodies against the catalytic domain of MMP9 through screening. The preparation method is simple and convenient, and is conducive to wide application.

[0022] The third aspect of the present application provides an application of anti-tumor and anti-inflammatory related nano antibodies in the preparation of drugs related to the prevention and treatment of tumors or inflammation; since anti-tumor and anti-inflammatory related nano antibodies can effectively inhibit the activity of MMP9 protease and can serve as MMP9 inhibitors, they are conducive to the application in the preparation of drugs related to the prevention and treatment of tumors or inflammation.

[0023] The fourth aspect of the present application provides an application of anti-tumor and anti-inflammatory related nano antibodies in the preparation of detection reagents or detection kits for detecting tumors or inflammation; since anti-tumor and anti-inflammatory related nano antibodies can effectively inhibit the activity of MMP9 protease and can serve as MMP9 inhibitors, they are conducive to the application in the preparation of detection reagents or detection kits for detecting tumors or inflammation.

[0024] The fifth aspect of the present application provides a drug for treating tumors or inflammation, which includes anti-tumor and anti-inflammatory related nanoantibodies; wherein the tumor includes breast tumors or colon tumors, and the inflammation includes enteritis; since the provided nanoantibody can effectively inhibit the activity of MMP9 protease and can serve as an MMP9 inhibitor, the nanoantibody can be used as a drug for preparing a drug for treating tumors or inflammation. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0026] Figure 1 This is the MMP9 catalytic domain recombinant protein immune library construction and nanobody screening process provided in the examples of the present application.

[0027] Figure 2 The examples of this application provide the expression, purification, affinity and inhibitory characterization of the candidate nanobodies.

[0028] Figure 3 This is an analysis diagram of the inhibitory effect of VHH02-8D on breast cancer cells in vitro provided in the examples of the present application.

[0029] Figure 4 This is an analysis diagram of the therapeutic effect of VHH02-8D on a mouse breast cancer model in vivo provided in the examples of the present application.

[0030] Figure 5 This is an analysis chart showing that VHH02-8D provided in the examples of the present application has a good therapeutic effect in an inflammatory bowel disease model.

[0031] Figure 6 This is the therapeutic effect of VHH02-8D provided in the examples of the present application in a mouse colon cancer model. DETAILED DESCRIPTION

[0032] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.

[0033] In this application, the term "and / or" describes the association relationship of associated objects, indicating that there may be three relationships. For example, A and / or B can mean: A exists alone, A and B exist at the same time, and B exists alone. A and B can be singular or plural. The character " / " generally indicates that the associated objects are in an "or" relationship.

[0034] In this application, "at least one" means one or more, and "plurality" means two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single items or plural items. For example, "at least one of a, b, or c", or "at least one of a, b, and c" can all mean: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, c can be single or multiple, respectively.

[0035] It should be understood that in the various embodiments of the present application, the size of the serial numbers of the above-mentioned processes does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.

[0036] The terms used in the embodiments of the present application are only for the purpose of describing specific embodiments, and are not intended to limit the present application. The singular forms "a", "an" and "the" used in the embodiments of the present application and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.

[0037] The weight of the relevant components mentioned in the embodiment description of the present application can not only refer to the specific content of each component, but also represent the proportional relationship between the weights of the components. Therefore, as long as the content of the relevant components is proportionally enlarged or reduced according to the embodiment description of the present application, it is within the scope disclosed in the embodiment description of the present application. Specifically, the mass in the embodiment description of the present application can be μg, mg, g, kg and other mass units known in the chemical industry.

[0038] The terms "first" and "second" are used only for descriptive purposes to distinguish objects such as substances from each other, and should not be understood as indicating or implying relative importance or implicitly indicating the number of indicated technical features. For example, without departing from the scope of the embodiments of the present application, the first XX may also be referred to as the second XX, and similarly, the second XX may also be referred to as the first XX. Thus, features defined as "first" and "second" may explicitly or implicitly include one or more of the features.

[0039] In a first aspect, an embodiment of the present application provides an anti-tumor and anti-inflammatory related nanoantibody, wherein the nanoantibody includes the nanoantibody VHH02-8D, wherein the amino acid sequence of the nanoantibody VHH02-8D is shown in Seq.ID NO.1.

[0040] The first aspect of the embodiment of the present application provides an anti-tumor and anti-inflammatory related nanoantibody, the nanoantibody includes the nanoantibody VHH02-8D, wherein the amino acid sequence of the nanoantibody VHH02-8D is as shown in Seq.ID NO.1; the nanoantibody VHH02-8D can specifically bind to the tumor and inflammation related protein MMP9, can effectively inhibit the activity of MMP9 protease, and can serve as an MMP9 inhibitor, and the provided nanoantibody VHH02-8D has a good therapeutic effect in mouse breast cancer, colon cancer and inflammatory bowel disease models, can significantly inhibit the metastasis of breast cancer, and the development of breast cancer and colon cancer, and can also effectively alleviate the inflammatory response of colitis by inhibiting the activity of MMP9 enzyme, and can be used to prepare anti-tumor and anti-inflammatory related drugs, with a wide range of applications.

[0041] In some embodiments, the amino acid sequence of Nanobody VHH02-8D is as shown in Seq.ID NO.1, and Seq.ID NO.1 is:

[0042] DVQLQESGGGLVQPGGSLRLSCAASGHTLYTLAIGWFRQAPGKEREVISCISNSGRST YFANSAKGRFTMSRDNAKNTVYLQMNSLKPEDTAVYYCAADFRPLGTCRDGGYHYWGQ GTQVTVSS.

[0043] In some embodiments, Nanobodies comprise four framework regions FR1, FR2, FR3, FR4 and three complementarity determining regions CDR1, CDR2, CDR3.

[0044] Among them, in the nano antibody VHH02-8D, the amino acid sequence of FR1 is shown in SEQ ID NO.2, and SEQ ID NO.2 is DVQLQESGGGLVQPGGSLRLSCAAS.

[0045] The amino acid sequence of FR2 is shown in SEQ ID NO.3, and SEQ ID NO.3 is GWFRQAPGKER.

[0046] The amino acid sequence of FR3 is shown in SEQ ID NO.4, which is ANSAKGRFTMSRDNAKNTVYLQMNSLKPEDTAVYYC.

[0047] The amino acid sequence of FR4 is shown in SEQ ID NO.5, and SEQ ID NO.5 is YWGQGTQVTVSS.

[0048] The amino acid sequence of CDR1 is shown in SEQ ID NO.6, and SEQ ID NO.6 is GHTLYTLAI.

[0049] The amino acid sequence of CDR2 is shown in SEQ ID NO.7, and SEQ ID NO.7 is EVISCISNSGRSTYF.

[0050] The amino acid sequence of CDR3 is shown in SEQ ID NO.8, and SEQ ID NO.8 is AADFRPLGTCRDGGYH.

[0051] In some embodiments, the base sequence of Nanobody VHH02-8D is as shown in Seq.ID NO.9, and Seq.ID NO.9 is

[0052] GATGTTCAGCTGCAGGAAAGCGGCGGCGGTCTGGTTCAGCCGGGTGGTAGCCTGCGTC

[0053] TGAGTTGTGCCGCAAGCGGTCATACCCTGTATACCCTGGCCATTGGTTGGTTTCGCCAG

[0054] GCACCGGGTAAAGAACGCGAAGTGATTAGCTGTATTAGCAATAGTGGCCGTAGTACCTA

[0055] TTTTGCAAATAGCGCAAAAGGTCGTTTTACCATGAGCCGTGATAATGCAAAAAATACCG

[0056] TGTATCTGCAGATGAATAGTCTGAAACCGGAAGATACCGCCGTTTATTATTGTGCAGCA

[0057] GATTTTCGTCCGCTGGGTACCTGTCGCGATGGTGGCTATCATTATTGGGGTCAGGGTACCCAGGTGACCGTTAGTAGT.

[0058] The obtained nanobody VHH02-8D is a nanobody specific for MMP9, and has high yield and good binding activity through prokaryotic expression. Nanobodies have many advantages over traditional antibodies, some of the main advantages include: (1) Small size: Nanobodies are small antibodies, usually composed of a single antigen binding domain, which enables them to more easily pass through cell membranes and tissues, enter the target area, and improve drug delivery efficiency. (2) High affinity: Nanobodies usually have high antigen affinity and can bind to target molecules more tightly, providing higher specificity and efficacy. (3) High stability: Nanobodies have strong physical and chemical stability and can maintain their activity under various environmental conditions, which is very beneficial for preparation, storage and transportation. (4) Simple humanization: Nanobodies can be easily humanized through engineering technology, reducing immunogenicity problems and reducing the risk of adverse reactions in drug treatment. (5) Microbial expression: Nanobodies can be produced through microbial expression systems (such as Escherichia coli), which improves preparation efficiency and reduces production costs. (6) Strong penetration: Due to their small size, nanobodies can more easily penetrate deep into tissues, including hard-to-treat sites such as solid tumors. (7) Ability to recognize hidden epitopes: Nanobodies can recognize some hidden antigen epitopes that are difficult to reach with traditional antibodies, which is very helpful for studying and treating specific diseases. (8) Highly customizable: Nanobodies can be customized through engineering technology to meet different diseases and treatment needs, including preparation of peptide binding, drug conjugation, etc.

[0059] In a second aspect, the present application provides a method for preparing anti-tumor and anti-inflammatory related nanobodies, comprising the following steps:

[0060] S01. Providing anti-tumor and anti-inflammatory related target protein antigens for alpaca immunization, collecting alpaca blood and extracting cDNA, and performing PCR amplification using cDNA as a template to obtain the target DNA fragment;

[0061] S02. Connecting the target DNA fragment to the vector for transformation to obtain the target DNA-vector library;

[0062] S03. Amplify the target DNA-vector library to obtain a phage library, then perform enrichment screening, and perform monoclonal antibody expression and purification to obtain anti-tumor and anti-inflammatory related nano-antibody sequences.

[0063] The second aspect of the present application provides a method for preparing anti-tumor and anti-inflammatory related nano-antibodies. The preparation method uses anti-tumor and anti-inflammatory related target protein antigens to immunize alpacas to obtain an immune library, and obtains specific nano-antibodies against the catalytic domain of MMP9 through screening. The preparation method is simple and convenient, and is conducive to wide application.

[0064] In step S01, anti-tumor and anti-inflammatory related target protein antigens are provided for alpaca immunization, alpaca blood is collected and cDNA is extracted, and PCR amplification is performed using cDNA as a template to obtain the target DNA fragment.

[0065] In some embodiments, the anti-tumor and anti-inflammatory related target protein antigen is MMP9 antigen. In some embodiments, the anti-tumor and anti-inflammatory related target protein antigen provided is MMP9 catalytic domain recombinant protein.

[0066] In step S02, the target DNA fragment is connected to a vector for transformation to obtain a target DNA-vector library.

[0067] In some embodiments, the vector cell is selected from the phagemid pComb3X.

[0068] In step S03, the target DNA-vector library is amplified to obtain a phage library, which is then enriched and screened, and monoclonal antibody expression and purification are performed to obtain anti-tumor and anti-inflammatory related nano-antibody sequences.

[0069] In some embodiments, in the enrichment screening step, 2 to 3 rounds of enrichment screening are performed.

[0070] In some embodiments, a library with a capacity of 3.45×10 9 After three rounds of screening, 30 positive clones were obtained from the library, and the affinity of these six nanobodies to the MMP9 catalytic domain recombinant protein was evaluated by ELISA method. Among them, VHH02-8D had the best affinity, so it was selected for subsequent experiments.

[0071] The third aspect of the embodiments of the present application provides the use of anti-tumor and anti-inflammatory related nano-antibodies in the preparation of drugs related to the prevention and treatment of tumors or inflammation.

[0072] The third aspect of the embodiment of the present application provides an application of anti-tumor and anti-inflammatory related nano antibodies in the preparation of drugs related to the prevention and treatment of tumors or inflammation; since anti-tumor and anti-inflammatory related nano antibodies can effectively inhibit the activity of MMP9 protease and can serve as MMP9 inhibitors, they are conducive to the application in the preparation of drugs related to the prevention and treatment of tumors or inflammation.

[0073] The fourth aspect of the embodiments of the present application provides the use of anti-tumor and anti-inflammatory related nano-antibodies in the preparation of detection reagents or detection kits for detecting tumors or inflammation.

[0074] The fourth aspect of the embodiment of the present application provides an application of anti-tumor and anti-inflammatory related nano antibodies in the preparation of detection reagents or detection kits for detecting tumors or inflammation; since anti-tumor and anti-inflammatory related nano antibodies can effectively inhibit the activity of MMP9 protease and can serve as MMP9 inhibitors, they are conducive to the application in the preparation of detection reagents or detection kits for detecting tumors or inflammation.

[0075] The fifth aspect of the embodiment of the present application provides a drug for treating tumors or inflammation, the drug including anti-tumor and anti-inflammatory related nano-antibodies; wherein the tumor includes breast tumor or colon tumor, and the inflammation includes enteritis.

[0076] The fifth aspect of the embodiment of the present application provides a drug for treating tumors or inflammation, and the drug includes anti-tumor and anti-inflammatory related nano antibodies; wherein the tumor includes breast tumors or colon tumors, and the inflammation includes enteritis; since the provided nano antibodies can effectively inhibit the activity of MMP9 protease and can serve as MMP9 inhibitors, the nano antibodies can be used as drugs for preparing drugs for treating tumors or inflammation.

[0077] The following describes the invention in conjunction with specific embodiments.

[0078] Example 1

[0079] A nano-antibody related to anti-tumor and anti-inflammation and its preparation method

[0080] Methods for preparing anti-tumor and anti-inflammatory related nanoantibodies Figure 1 As shown, specifically including the following:

[0081] (I) Immune library construction

[0082] 1. Immunization: Select an alpaca over 8 months old, take 2 ml of negative serum and save it for later use. After 3-5 days of observation, start the immunization, with an immunization dose of 1 mg / time / head. Perform three immunizations on days 0, 14 and 18 respectively (1 mg of antigen is mixed and emulsified with Freund's complete adjuvant, and multiple subcutaneous immunization injections are performed on the back of the alpaca at more than 8 points), and collect blood for serum titer detection 7 days after immunization. If the titer of the three immunization tests is qualified, the immunization is strengthened. After 5 days, collect 80 ml of peripheral blood, separate the serum, add Trizol and save it for later use.

[0083] 2. cDNA acquisition: Total RNA was extracted using the Trizol method and reverse transcribed using the Takara reverse transcription kit.

[0084] 3. PCR amplification: For the first round of PCR of the antibody gene, cDNA was used as a template. The amplification system (20 μL) of each primer pair was shown in Table 1, and the amplification program was shown in Table 2.

[0085] Table 1

[0086]

[0087] Configure and perform PCR reaction according to Table 2 below:

[0088] Table 2

[0089]

[0090] The second round of PCR of the antibody gene sequence uses the 700bp target fragment of the first round of PCR product as a template. The amplification system (20 μL) of each pair of primers is shown in Table 1, and the amplification program is shown in Table 2. The second round of amplified fragments were recovered by gel recovery kit according to the instructions, and 2 μg of the recovered fragments and 10 μg of pComb3X vector were digested with sfiI enzyme, respectively, and reacted in a 50°C water bath for 60 minutes, and then gel recovery was performed. The vector recovered by gel cutting was connected with the target fragment, and the connection was carried out at 16°C overnight, and the reaction system was (600 μL). (The connection system is shown in Table 3).

[0091] Table 3

[0092]

[0093] 4. Electroporation: The purified ligation product was mixed with the XL1-Blue competent state in an ice bath, and 80 μL / cup was dispensed into an electroporation cup, and electroporated at 1800V. After electroporation, the mixture was transferred into a 2×YT medium containing ampicillin and tetracycline, and the volume was fixed to 200mL using 2×YT. The library after the fixed volume was shaken and cultured for 1 hour at 37°C and 250rpm, and the antibody bacterial liquid library was obtained at this time. 100 μL of bacterial liquid was taken from the library and diluted 1000 times using 2×YT medium according to the 10-fold dilution method (100 μL bacterial liquid + 900 μL 2×YT), and 100 μL of the diluted bacterial liquid was applied to a 2×YT (containing ampicillin and tetracycline) semi-solid culture medium plate, and cultured overnight at 37°C. The monoclonal colonies were counted the next day and the number of transformants was calculated. Calculate the number of transformants in the transformant library: single clone colony count × dilution factor per unit volume × total library volume = 214 × 100,000 × 200 = 4.28 × 10 9 .

[0094] 5. Library quality analysis: 36 clones were randomly selected from the library plate for sequencing, including 3 original vectors, 3 overlapping peaks, and 1 incorrect sequence. The sequence accuracy was 80.5%. The library titer was calculated as follows: monoclonal colony count × unit volume dilution factor × total library volume × accuracy = 214 × 100000 × 200 = 4.28 × 10 9 ×80.5%=3.45×10 9 .

[0095] 6. Phage library expression amplification: After the remaining library solution in the previous step was shaken at 37°C and 250rpm for 1 hour, VCSM13 was added to help the phage to infect for half an hour, and then further cultured at 37°C and 250rpm for 1 hour. Finally, the bacterial precipitate was collected by centrifugation and refloated in 100mL 2×YT medium (containing ampicillin, tetracycline and kanamycin), and expression amplification was carried out overnight at 30°C and 225rpm. The supernatant was collected the next day, and 4% PEG800 and 3% Nacl were used for ice bath and centrifugation to obtain phage precipitate. The obtained phage precipitate was resuspended and dissolved in PBS (pH 7.4) and sterilized by filtration with a 0.2 μm syringe filter. 10 μL of the filtered library was taken and diluted 108 times using the 100-fold dilution method (10 μL + 990 μL) of 2×YT medium. 10 μL of the dilution was taken to infect 100 μL of XL1-blue. After 30 minutes, 2×YT semi-solid medium plates were coated. The number of monoclonal colonies was counted the next day to calculate the phage concentration of the amplified library. The filtered library was added with 7% DMSO and frozen at -80°C for storage.

[0096] (II) Nanoantibody Screening

[0097] 1. Coating: Prepare antigen MMP9 with PBS at a final concentration of 25 μg / mL, add 100 μL / well antigen protein to a high-absorption immune 8-well strip, coat overnight at 4°C, then discard the solution and wash with PBST solution 5 times;

[0098] 2. Blocking: Add 200 μL of blocking solution (alternately use 5% skim milk and 0.5% BSA) to block the reaction wells, incubate at room temperature for 1 hour, then discard the solution and wash with PBST solution 5 times;

[0099] 3. Add library: add 100 μL / well amplified phage library, incubate at room temperature for 1 hour, discard the liquid, and wash with PBST 5 times;

[0100] 4. Phage elution: Add 100 μL / well of 0.1M HCl solution, incubate at room temperature for 10 min to elute the phages that specifically bind to the antigen, collect 800 μL of the eluate in a 1.5 mL centrifuge tube, add 64 μL of 1M Tris-HCl and mix thoroughly to neutralize the HCl in the eluted phages, and store at 4°C;

[0101] 5. Infect bacteria: Add the eluted phage to E. coli TG1 (OD600 nm = 0.5) cultured in 10 mL of 2×YT (containing 10 mg / L Tet) liquid medium, incubate at 37°C for 1 h; add 40 mL of 2×YT (containing 2% glucose, 100 mg / L Amp) liquid medium, and culture at 37°C, 200 rpm shaking until OD600 nm = 0.5;

[0102] 6. Helper phage superinfection: Add helper phage VSCM13 to 10 mL of the bacterial solution. 10 The final concentration was pfu / mL, and the cells were cultured at 37°C with shaking at 200 rpm for 1 h;

[0103] 7. Screening and amplifying phages: centrifuge 50 mL of bacterial solution at 5000 rpm for 10 min, discard the supernatant (remove glucose, free phages, and free helper phages), resuspend the precipitate in 50 mL of 2×YT (containing 100 mg / L Amp, 50 mg / L Kan, 50 μM IPTG) liquid culture medium, transfer the liquid to a 250 mL Erlenmeyer flask, and culture overnight at 37°C, 200 rpm (the phages in the library are resistant to ampicillin, and the helper phage VSCM13 is resistant to kanamycin, so adding double antibiotics can screen for E. coli TG1 infected by both the library phage and the helper phage).

[0104] 8. Centrifuge the overnight culture at 7000rpm for 20min, take 40mL of supernatant, add 10mL of PEG 8000 / NaCl solution (supernatant of bacterial solution: PEG 8000 / NaCl = 1:4), mix well and place on ice for 1h to precipitate phages. The remaining supernatant was stored at 4℃ and used to determine the titer of each round of screening;

[0105] 9. Centrifuge at 4°C (10,000 rpm, 20 min) and discard the supernatant. Resuspend the precipitate with 1 mL of PBS and centrifuge at 4,000 rpm for 1 min to remove the substances insoluble in PBS. The phage library for the next round of screening is obtained, which is one round of screening.

[0106] 10. Determine the titer of the obtained phage library in the same manner as steps 8-9 in 1.

[0107] 11. Repeat the above steps for 3 rounds of screening. Calculate the degree of enrichment and screening effect by titer. When the enrichment ratio (ratio to the recovery rate of the first round of screening) is greater than 100 times, the screening is considered sufficient and ELISA detection is performed.

[0108] 12. Isolation of phage monoclonal clones: Add the eluted phage library from the third round of screening to 10 mL of E. coli TG1 (OD 600nm = 0.5) cultured in 2×YT liquid medium (containing 10 mg / L Tet), incubate at 37°C for 1 h; -1 to 10 -4100 μL of each dilution was evenly spread on a 2×YT (containing 100 mg / L Amp) solid plate and cultured at 37°C overnight. 96 obvious single colonies were randomly picked from the overnight cultured plate and placed in a 96-well deep-well plate with 400 μL of 2×YT (containing 2% glucose, 100 mg / L Amp) liquid medium. The plates were cultured at 37°C, 200 rpm until OD 600nm = 0.5. 400 μL of 2×YT liquid medium and a final concentration of 100 mg / L Amp, 50 mg / L Kan, 50 μM IPTG, and 10 10 VSCM13 helper phage was cultured overnight at 37°C and 200 rpm. The supernatant was obtained by centrifugation at 5000 rpm for 10 min. The supernatant was the monoclonal phage fused with the single domain antibody. The supernatant was transferred to a sterile 96-well deep-well plate with a sealing film and stored at 4°C for later use.

[0109] 13.ELISA detection: Prepare the antigen MMP9 with a final concentration of 25 μg / mL in PBS, add 100 μL / well of antigen protein to a high-absorption 96-well ELISA plate, coat overnight at 4°C, discard the liquid, and wash 5 times with PBST; at the same time, coat BSA with the same concentration as a negative control; add 200 μL of blocking solution (5% skim milk), block at room temperature for 1 hour, discard the liquid, and wash 5 times with PBST;

[0110] 8) Add 100 μL of the supernatant of the isolated and cultured single phage respectively, shake lightly at room temperature for 2 hours, discard the liquid, and wash 5 times with PBST; add 100 μL of 8000-fold diluted M13 Bacteriophage Antibody (HRP), MouseMab to each well, incubate at room temperature for 1 hour, discard the antibody, and wash 5 times with PBST; add 100 μL of TMB substrate and shake lightly at room temperature until the sample obviously produces blue, add 100 μL of 1M HCl to terminate the reaction and measure the absorbance at OD450 nm; select the supernatant of the monoclonal bacterial solution with obvious positive, take 100 μL of the supernatant each, repeat the above steps as the experimental group, and replace the antigen S1 with the same concentration of BSA coated on the ELISA plate, and perform the same experiment as the experimental group as the negative control group, and judge the positive clones by the ratio of the absorbance of the experimental group to the control group, so as to screen out the MMP9-specific nanoantibody and send it for sequencing.

[0111] (III) Expression, purification and characterization of nanobodies

[0112] 1. Expression and purification methods include:

[0113] 1) The pET23a-VHH recombinant plasmid was transformed into expression competent cells E. coli BL21 (DE3) according to the instructions and spread on solid culture medium.

[0114] 2) Pick a single colony and place it in 6 mL of LB medium, culture it at 37°C, 200 rpm for 5 h, then transfer it to fresh 250 mL of LB medium at a ratio of 1:100 and culture it at 37°C, 200 rpm; when the OD 600nm of the bacterial solution reaches 0.6-0.8, add IPTG inducer with a final concentration of 0.1 mM and culture it at 16°C for 15 h.

[0115] 3) After the culture, the bacterial solution was centrifuged at 4000rpm for 10min to collect the bacteria, and then the bacteria were resuspended in Binding buffer (50mM sodium dihydrogen phosphate, 300mM sodium chloride, 20mM imidazole, pH 7.4) and ultrasonically disrupted (350W, work 5s, off 3s, time 20min). Then, the solution was centrifuged at 18000rpm, 4℃ for 15min to collect the precipitate;

[0116] 4) The precipitate was resuspended and washed with PBS containing 2M urea and 1mM EDTA, and then centrifuged. Subsequently, the precipitate was resuspended in PBS containing 1% TritonX100, and then ultrasonically washed and centrifuged. An appropriate amount of 6M urea solution was added to the precipitate to fully dissolve it, and then dialyzed in PBS at 4°C overnight to collect the protein sample.

[0117] Performance testing and result analysis

[0118] (I) Sequencing and SDS-PAGE analysis

[0119] The candidate antibodies were sent for sequencing and then expression vectors were constructed for expression and purification and named VHH02-8D, VHH02-4Y, VHH02-6C, VHH02-9J, VHH02-2F and VHH02-3G respectively; the protein samples after expression and purification were detected by SDS-PAGE electrophoresis; the protein concentration was measured by Pierce TM BCA protein quantification kit was used for determination. Figure 2 Shown in a is the naming of 6 candidate nanobodies and the SDS-PAGE gel image after expression and purification.

[0120] The obtained sequence of the anti-tumor and anti-inflammatory related nano antibody sequence VHH02-8D is:

[0121] DVQLQESGGGLVQPGGSLRLSCAASGHTLYTLAIGWFRQAPGKEREVISCISNSGRSTYFANSAKGRFTMSRDNAKNTVYLQMNSLKPEDTAVYYCAADFRPLGTCRDGGYHYWGQGTQVTVSS.

[0122] (II) ELISA method to detect the affinity of nanoantibodies to MMP9: Coat the antigen and block, and operate the same as the above ELISA; add 100 μL / well of single domain antibody diluted in multiple ratios, incubate at room temperature for 1 hour, discard the liquid, and wash 5 times with PBS; add 100 μL of Anti-HA-tag mAb-HRP-DirecT diluted 1:3000 to each well, shake gently at room temperature for 1 hour, discard the antibody and wash 5 times with PBST; add 100 μL of TMB substrate and shake gently at room temperature until the sample obviously produces blue color, then add 100 μL of 1M HCl to terminate the reaction, and measure its OD value at OD 450nm.

[0123] The results are as follows Figure 2 The results of b showed that the six candidate nanoantibodies all had good affinity for MMP9, among which VHH02-8D was the best.

[0124] (III) Biolayer interferometry (BLI) detection of the affinity of nanoantibodies to MMP9:

[0125] 1) Biotinylation of MMP9: Biotin-N-succinimidyl ester (NHS-Biotin) was used to biotinylate the antigen MMP9 according to its instructions, so that it can be connected to the streptavidin biosensor equipped with the molecular interaction instrument and used for detection;

[0126] 2) Dilute the biotinylated MMP9-Bio to 0.1 mg / mL with PBS; dilute the nanoantibody to 4 different concentrations with PBS; turn on the machine and set the program according to the instructions, and hydrate the streptavidin biosensor for more than 10 minutes in advance; then use 150 μL PBS to balance the sensor until the baseline is stable; put 150 μL MMP9-Bio into the sample tank to couple the antigen molecule to the sensor; use 150 μL PBS to balance the sensor until the baseline is stable; use 150 μL of a specific concentration of single-domain antibody to bind to the antigen molecule coupled to the sensor; put the biosensor combined with the nanoantibody into 150 μL PBS to measure the dissociation of the antigen-antibody molecule;

[0127] 3) reloading a new streptavidin biosensor to couple with the antigen molecule, and measuring the binding and dissociation of multiple different concentrations of antibodies and antigen molecules;

[0128] 4) After completing the binding and dissociation of multiple concentrations, the data were analyzed using the instrument-specific analysis tool BLItz Pro 1.3.0.2 to obtain the equilibrium dissociation constant kD.

[0129] The results showed that VHH02-8D bound to MMP9 very quickly, but there was a certain degree of dissociation, e.g. Figure 2As shown in c, the BLI technology analyzed the interaction between VHH02-8D (700nM, 350nM, 150nM) and MMP9, and the affinity constant kD was calculated according to the instrument supporting software: 20.63nM, indicating that VHH02-8D has an ideal affinity for MMP9.

[0130] (IV) Detection of the inhibition of MMP9 enzyme activity by nanoantibodies using a gelatin degradation kit: Nanoantibodies of different concentrations were diluted and incubated with 1 μM antigen at room temperature for 1 hour. The mixture was then added to the reaction wells according to the instructions of the kit (ab234057). The real-time fluorescence curve was detected on an ELISA reader to detect the inhibitory effect of the nanoantibody on MMP9 enzyme activity.

[0131] The results are as follows Figure 2 As shown in d, VHH02-8D has a significant inhibitory effect on MMP9 enzyme activity, and has a 50% inhibitory effect at a concentration of 125 nM.

[0132] (V) Nanoantibody VHH02-8D has an inhibitory effect on the migration and invasion of breast cancer cell lines in vitro

[0133] 1. Scratch test: 1.2×10 6 4T1 cells were plated in 6-well plates and cultured overnight until the cell density reached 90%. The next day, the culture medium was removed and 1 mL of PBS was added to each well. A 200 μL pipette tip was used to scratch the bottom of the well. PBS was removed and 2 mL of culture medium containing 200 μg / mL VHH02-8D was added to each well to continue culturing the cells. The cell scratches were photographed under a microscope every 24 hours and the healing rate was calculated.

[0134] 2. Transwell: Place the matrixgel in a 4°C refrigerator overnight to melt, use pre-cooled PBS to dilute the matrixgel to the working concentration, add 800 μL of diluted matrixgel to each transwell upper chamber and place it in a 37°C incubator to solidify the matrixgel. After 1.5 hours, remove the culture plate, resuspend the 4T1 cells in serum-free culture medium and add them to the matrixgel, then place the tranwell upper chamber with cells on the lower chamber containing 1 mL of full culture medium and place it in the incubator. After 24 hours, remove the upper chamber and remove the cell suspension and matrixgel in the upper chamber. After staining with crystal violet and washing with PBS, use a microscope to take pictures of the cells on the bottom membrane of the upper chamber and count them to calculate the invasion efficiency.

[0135] The results are as follows Figure 3As shown in a, after adding VHH02-8D for co-culture, there was no significant change in the cell scratches of the VHH02-8D group compared with the control group after 48 hours, while the scratch area of ​​the control group was significantly reduced after 48 hours. According to the wound healing rate analysis, there was a significant statistical difference between the VHH02-8D group and the control group, indicating that VHH02-8D can strongly inhibit the migration of 4T1 cells. Figure 3 Figure b shows the results of using the Transwell assay to detect the invasion of 4T1 cells by VHH02-8D. After adding VHH02-8D, the number of cells passing through the small holes was significantly reduced, and there was a significant statistical difference compared with the control group, indicating that VHH02-8D can effectively inhibit the invasion of 4T1 cells. VHH02-8D has a significant inhibitory effect on the invasion of breast cancer cell line 4T1 in vitro.

[0136] (VI) VHH02-8D has a significant therapeutic effect on breast cancer mice in vivo

[0137] 1. Establishment of mouse breast cancer model: 4T1-luc cell line was cultured in RPMI-1640 medium until the logarithmic growth phase, and the cells were diluted to 6×10 with physiological saline after digestion. 5 / mL and placed on ice. Six-week-old BALB / c mice were injected with 100 μL of 4T1-luc cell suspension into the tail vein of each mouse. Each mouse was injected intraperitoneally with 100 μg of VHH02-8D per day, and the weight and survival of the mice were monitored and recorded.

[0138] The results are as follows Figure 4 As shown in a, after modeling and drug treatment, the size of the tumor was captured by fluorescence using in vivo imaging technology on the 15th day. The results showed that VHH02-8D alone can limit the metastasis of breast cancer cells to the lungs. At the same time, we also used the method of combining PDL1 antibody with VHH02-8D for treatment, such as Figure 4 As shown in a, VHH02-8D nanobody 100μg / mouse (5mg / kg) or PDL1 (200μg / mouse) (10mg / kg) was injected, and fluorescence was taken on the 15th day of modeling to indicate tumor size. The results showed that the protective effect of VHH02-8D was comparable to that of PDL1 antibody, and the combined treatment of the two could significantly inhibit the metastasis of breast cancer cells to the lungs.

[0139] Figure 4 b represents the survival curves of the blank group, tumor control group, VHH02-8D group, PDL1 group and VHH02-8D+PDL1 group. The results show that VHH02-8D alone can effectively slow down the death time of breast cancer mice, and its effect is equivalent to that of PDL1 antibody treatment. When the two are used in combination, they can greatly prolong the survival time of breast cancer mice.

[0140] The lung weights of the blank group, control group, mice injected with VHH02-8D alone, mice injected with VHH02-8D combined with PDL1 antibody, and mice injected with PDL1 antibody were measured. Figure 4 As shown in c, it can be seen that the lung weight of mice treated with VHH02-8D alone was significantly reduced, indicating that the number of tumor metastases to the lungs was significantly reduced, and the effect was equivalent to that of injecting PDL1 antibodies alone. When the two were combined for treatment, the metastasis of breast cancer cells to the lungs was significantly inhibited, and the lung weight was significantly reduced.

[0141] Further, the lung cells were stained, e.g. Figure 4 As shown in d, the lung cell staining analysis diagrams of the blank group, tumor control group, VHH02-8D group, PDL1 group and VHH02-8D+PDL1 group under a 20x microscope are shown; the results show that VHH02-8D treatment alone limits the metastasis of breast cancer cells to the lungs, and the number of metastases is significantly reduced, which is equivalent to the effect of injecting PDL1 antibody alone. When the two are combined for treatment, the metastasis of breast cancer cells to the lungs can be significantly inhibited. Therefore, VHH02-8D can be used as a potential drug for the treatment of breast cancer, and the therapeutic effect can be greatly increased by combining it with PDL1 antibody.

[0142] (VII) Effect of VHH02-8D on colitis mice in vivo

[0143] 1. Experimental mouse grouping: Female C57BL / 6J mice were randomly divided into three groups: blank control group, DSS group and VHH02-8D group, with 5 mice in each group. The mice were adaptively raised in this laboratory for 7 days, and their diet, activity, defecation, etc. were observed and weighed.

[0144] 2. Mouse intervention method: The mice in the blank control group were fed with pure water throughout the experimental period, while the mice in the DSS group and VHH02-8D group were fed with 2.5% DSS aqueous solution for 7 days; the mice in the treatment group were intraperitoneally injected with 2.5 mg / kg VHH02-8D (dissolved in normal saline) on days 1, 3, 5, 5.5, 6, and 6.5, respectively; the DSS group and the blank control group were injected with an equal volume of normal saline in the same manner.

[0145] 3. Record of mouse condition: Record the initial body weight when starting to feed DSS and record it as day 0. Record the weight of mice every day and observe the characteristics of stool and blood in stool.

[0146] 4. Mouse killing and specimen collection: Specimens were collected and mice were killed on the 7th day. The mice were anesthetized with chloral hydrate and blood was collected from the eyeballs. The abdominal cavity was opened to collect the intact colorectum from the anus to the cecum of the mice, and the colon length was measured, recorded and compared. The colon was cleaned to remove fecal debris, and the distal end of the colon was fixed with an appropriate amount of 4% polyformaldehyde. After paraffin fixation and sectioning, HE staining was performed.

[0147] In experimental colitis, the method for evaluating the degree of inflammation is generally to calculate the DAI score, which is based on the weight change, stool characteristics and blood in the stool of the mouse. DAI = body mass index score + stool shape score + blood in the stool score. The higher the score, the more severe the colitis symptoms. The specific scoring criteria are shown in Table 4.

[0148] Table 4 Disease Activity Index Scoring Criteria

[0149]

[0150] The pathological section scoring is mainly based on the damage to the epithelial barrier and the degree of infiltration of inflammatory cells. The entire intestinal pathological section is observed under a microscope (40X and 100X), and the intestinal inflammation, epithelial ulcers and crypt damage are scored separately. The specific scoring rules are shown in Table 5, and the total score is the sum of the three scores.

[0151] Table 5 Scoring criteria for pathological sections

[0152]

[0153] Tissue paraffin sections and hematoxylin-eosin (HE) staining

[0154] The tissue was dehydrated, transparent, and then embedded in paraffin and sliced. The slices were dried at 45°C and can be used for subsequent experiments.

[0155] Dewaxing and rehydration: Soak the slides in xylene for 2 times, 5 minutes each time to remove the paraffin in the slices; then soak them in 100%, 90%, 80% and 70% alcohol respectively, 2-3 minutes each time, making sure that the slides do not dry out; finally, wash them in ddH2O for 2 times, 2 minutes each time, and then stain them;

[0156] Staining: Place the sections rinsed with deionized water in a hematoxylin aqueous solution for 10-30 minutes, rinse with tap water for 2 seconds; fade in 1% hydrochloric acid ethanol for 30 seconds; turn blue with tap water for 20 minutes; place the sections in 50% and 80% ethanol for 2 minutes each; stain with eosin ethanol solution for 1-2 minutes;

[0157] Dehydration and transparency: Place in 95%, 100% I, and 100% II ethanol, respectively, for 2 min each; then place in xylene I and xylene II, respectively, for 2 min;

[0158] Neutral gum sealing: drop neutral gum on the slices, cover with coverslip for sealing, let dry at room temperature, label and set aside.

[0159] Optical microscopy observation: The stained sections were observed under a microscope to compare the pathological changes in the colon of mice in different groups, and photos were taken using an automatic imaging system.

[0160] The results are as follows Figure 5 As shown in a, the weight changes and disease activity index were observed and recorded every day. The results showed that the weight of mice in the DSS group decreased significantly after the 5th day. Compared with the 0th day, the weight of mice before being killed on the 7th day decreased by an average of 17.5%; while the weight of mice in the VHH02-8D group began to decrease on the 6th day, and the average weight decreased by only 5.2% on the 7th day; from the perspective of the disease activity index, the final score of VHH02-8D was 4.5 on average, while the final average score of the DSS group was as high as 11 points; and the length of the colon of the mice was Figure 5 b, The colon of the VHH02-8D group was also significantly longer compared with that of the DSS group, indicating that VHH02-8D treatment can significantly alleviate the body weight loss and disease symptoms of DSS-induced colitis.

[0161] Furthermore, the colon tissue sections of the three groups of mice in the mouse colitis experiment were stained with HE and compared. Figure 5 As shown in c, the colon tissue sections of the three groups of mice were obtained under the microscope at 40 times and 100 times magnification after HE staining. Compared with the DSS group, the injection of VHH02-8D significantly improved the infiltration of inflammatory cells, crypt destruction and epithelial ulcers in the colon tissue of mice, and the histopathological scores were also significantly reduced.

[0162] The results fully demonstrated that the specific MMP9 inhibitor VHH02-8D can effectively alleviate the inflammatory response of colitis by inhibiting the activity of MMP9.

[0163] (VIII) Effects of VHH02-8D on colon cancer mice in vivo

[0164] 1. Experimental mouse grouping: Female C57BL / 6J mice were randomly divided into three groups: blank control group, DSS group and VHH02-8D group, with 8 mice in each group. The mice were adaptively raised in this laboratory for 60 days, and their diet, activity, defecation, etc. were observed and weighed.

[0165] 2. Mouse intervention method: The mice in the blank control group were fed with pure water throughout the experimental period, while the mice in the DSS group and the VHH02-8D group were fed with 2.5% DSS aqueous solution for 5 consecutive days on days 5, 26 and 47, respectively, and then switched to distilled water; AOM (12.5 mg / kg) was injected intraperitoneally on days 0 and 43; the mice in the VHH02-8D group were injected intraperitoneally with VHH02-8D (dissolved in saline) 2.5 mg / kg every other day; the DSS group and the blank control group were injected with an equal volume of saline in the same manner.

[0166] 3. Record of mouse condition: Record the initial body weight when starting to feed DSS and record it as day 0. Record the weight of mice every day and observe the characteristics of stool and blood in stool.

[0167] 4. Mice killing and specimen collection: Specimens were collected and mice were killed on the 60th day. The mice were anesthetized with chloral hydrate and blood was collected from the eyeballs. The abdominal cavity was opened to collect the intact colorectum from the anus to the cecum of the mice, and the colon length was measured, recorded and compared, and the tumors on the colon were counted. The colon was cleaned to remove fecal debris, and the distal end of the colon was fixed with an appropriate amount of 4% paraformaldehyde. After paraffin fixation and sectioning, HE staining was performed.

[0168] The results are as follows Figure 6 As shown in a, a mouse colon cancer model was established by inducing 2.5% DSS, and VHH02-8D inhibitor solution or saline (DSS group) was intraperitoneally injected during the DSS treatment stage. The group fed with distilled water served as a blank control group to observe the therapeutic effect of VHH02-8D in colon cancer.

[0169] like Figure 6 As shown in b, it is the weight analysis chart of three groups of mice in the mouse colitis-related colon cancer experiment, as well as the disease activity index. The weight changes of mice in different experimental groups were observed every day. Figure 6 As shown in the left figure of b; Figure 6 The right side of b is the analysis chart of the comprehensive scores of diarrhea, blood in the stool and weight change of the three groups of mice in the mouse colitis-related colon cancer experiment. The results show that the weight of the mice in the VHH02-8D group is similar to that of the blank control group, without obvious weight loss, while the weight loss of the mice in the DSS group is obvious, especially in the DSS treatment stage, the weight dropped sharply. From the perspective of the disease activity index, the score of the mice in the VHH02-8D group is significantly lower than that of the DSS group, indicating that the VHH02-8D treatment can effectively improve the symptoms of blood in the stool, diarrhea and weight loss in mice.

[0170] Figure 6Figure c shows the colons of the three groups of mice and the number of tumors on the colons. As can be seen in the figure, the number of tumors in the colons of the VHH02-8D treatment group was significantly reduced compared with the DSS group, and there was a significant statistical difference, indicating that VHH02-8D treatment can reduce tumor formation in the colon.

[0171] Further, HE staining of colon tissue was performed, and the staining results were as follows Figure 6 As shown in d, the figure shows the colon tissue sections of the blank control group, DSS group and VHH02-8D group in the mouse colon cancer experiment, which are microscope images with magnifications of 40 times and 100 times respectively after HE staining; the results of colon tissue HE staining show that compared with the DSS group, the injection of VHH02-8D significantly improved the infiltration of inflammatory cells, crypt destruction and epithelial ulcers in the mouse colon tissue. At the same time, the occurrence of tumors was significantly restricted, and the number of colon cancer tumors was significantly reduced. The results fully show that the specific MMP9 inhibitor VHH02-8D can effectively alleviate the development of colon cancer by inhibiting the activity of MMP9.

[0172] In summary, this application uses MMP9 catalytic domain recombinant protein to immunize alpacas to obtain an immune library targeting the MMP9 catalytic domain, and screens specific nanobodies targeting the MMP9 catalytic domain to develop new MMP9 nanoantibody inhibitors for the treatment of related cancers and inflammatory diseases. We have successfully constructed a library with a capacity of 3.45×10 9After three rounds of screening, 30 positive clones were obtained. Then we selected the first six for expression and purification, and evaluated the affinity of these six nanobodies to the recombinant protein of the catalytic domain of MMP9 by ELISA method. Among them, VHH02-8D had the best affinity, so it was selected for subsequent experiments. The affinity kD of VHH02-8D and the catalytic domain of MMP9 was further detected by biomembrane interferometry technology, which was 20.63nM; and the inhibitory effect on the activity of MMP9 protease was detected by small molecule fluorescent substrate. The inhibitory effect of VHH02-8D on the activity of MMP9 protease was very obvious, and only 125nM of nanoantibody could achieve 50% inhibition, indicating that VHH02-8D has great potential as an MMP9 inhibitor for the treatment of related diseases. Therefore, the breast cancer cell line 4T1 was first used to verify that VHH02-8D had a significant inhibitory effect on the metastasis and invasion of the breast cancer cell line 4T1 through scratch experiments and invasion experiments. Subsequently, mouse tumor models such as breast cancer and colon cancer were used to verify that VHH02-8D had a good therapeutic effect on cancer models with high MMP9 expression in vivo. In the breast cancer model, a treatment method combining VHH02-8D with anti-PDL1 antibodies was developed, which greatly slowed down the occurrence and progression of breast cancer and significantly prolonged the survival time of breast cancer model mice. In addition to playing a role in cancer models, VHH02-8D can also significantly inhibit the bloody stool symptoms associated with ulcerative colitis in inflammatory bowel disease models, while reducing the diarrhea symptoms associated with ulcerative colitis. Therefore, this study developed a new MMP9 inhibitor based on nanoantibodies, and for the first time found that VHH02-8D can treat a variety of diseases such as breast cancer, colon cancer, and colitis, and is expected to be used as a broad-spectrum anticancer drug and inflammatory treatment drug.

[0173] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present application should be included in the protection scope of the present application.

Claims

1. A nano-antibody related to anti-tumor and anti-inflammation, It is characterized in that The nanobody is an anti-matrix metalloproteinase 9 nanobody, and the nanobody is nanobody VHH02-8D, wherein the amino acid sequence of the nanobody VHH02-8D is shown in Seq.ID NO.

1.

2. The anti-tumor and anti-inflammatory related nanoantibodies according to claim 1, It is characterized in that The nanobody comprises four framework regions FR1, FR2, FR3, FR4 and three complementary determining regions CDR1, CDR2, CDR3; wherein, in the nanobody VHH02-8D, the amino acid sequence of FR1 is shown in SEQ ID NO.2, the amino acid sequence of FR2 is shown in SEQ ID NO.3, the amino acid sequence of FR3 is shown in SEQ ID NO.4, the amino acid sequence of FR4 is shown in SEQ ID NO.5, the amino acid sequence of CDR1 is shown in SEQ ID NO.6, the amino acid sequence of CDR2 is shown in SEQ ID NO.7, and the amino acid sequence of CDR3 is shown in SEQ ID NO.

8.

3. The anti-tumor and anti-inflammatory related nanoantibodies according to claim 1, It is characterized in that The base sequence of the nanobody VHH02-8D is shown in Seq.ID NO.

9.

4. Use of the anti-tumor and anti-inflammatory nanoantibodies according to any one of claims 1 to 3 in the preparation of drugs for preventing and treating tumors or inflammation, in, The tumor includes a breast tumor or a colon tumor, and the inflammation includes enteritis.

5. Use of the anti-tumor and anti-inflammatory nanoantibodies according to any one of claims 1 to 3 in the preparation of a detection reagent or a detection kit for detecting tumors or inflammation, in, The tumor includes a breast tumor or a colon tumor, and the inflammation includes enteritis.

6. A drug for treating tumors or inflammation, It is characterized in that The drug comprises the anti-tumor and anti-inflammatory related nanoantibodies according to any one of claims 1 to 3; wherein the tumor comprises a breast tumor or a colon tumor, and the inflammation comprises enteritis.

Citation Information

Patent Citations

  • Single-domain antibody specifically for MMP9 protein ZnMc structural domain as well as product and application thereof

    CN110885375A

  • MMP-9 nano antibody as well as preparation method and application thereof

    CN113698486A